The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback